PMID- 33000160
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20230216
IS  - 1541-6100 (Electronic)
IS  - 0022-3166 (Linking)
VI  - 150
IP  - Suppl 1
DP  - 2020 Oct 1
TI  - l-Histidine Supplementation in Adults and Young Children with Atopic Dermatitis 
      (Eczema).
PG  - 2576S-2579S
LID - 10.1093/jn/nxaa200 [doi]
AB  - Atopic dermatitis (AD) is an incurable, inflammatory skin condition that is 
      prevalent ( approximately 20%) in young children. There is an unmet clinical need, particularly 
      in children, for safe interventions that target the etiology of the disease. 
      Deficiencies in the skin barrier protein, filaggrin (FLG) have been identified as 
      major predisposing factors in AD. In mammals, l-histidine is rapidly incorporated 
      into epidermal FLG and subsequent FLG proteolysis releases l-histidine as an 
      important natural moisturizing factor (NMF). It has therefore been hypothesized 
      that l-histidine supplementation would be a safe approach to augment both FLG and 
      the NMF, enhance skin barrier function, and reduce AD severity. In a clinical 
      pilot study, adult subjects (n = 24) with AD took either a placebo or 4 g oral 
      l-histidine daily for 8 wk. Unlike the placebo, l-histidine reduced AD (34% 
      reduction in SCORing Atopic Dermatitis scores; P < 0.003) after 4 wk. Nine and 8 
      adverse events (AEs), and 1 and 0 severe AEs were recorded in the l-histidine or 
      placebo groups, respectively, with no AE being causally related to l-histidine 
      ingestion. A survey of adults (n = 98) taking 4 g l-histidine daily reiterated a 
      lack of causal AEs and also reported a 33% reduction in topical corticosteroid 
      use. A placebo-controlled, clinical pilot study conducted in young children with 
      AD (n = 49; mean age 3.5 y) taking 0.8 g l-histidine daily, showed that eczema 
      area and severity index scores were reduced by 49% (P < 0.02) at 12 wk, whereas a 
      placebo had no effect. The children taking l-histidine had 50 minor AEs (compared 
      with 39 on placebo), with 78% considered as "not," 18% "unlikely," and 4% 
      "possibly" related to l-histidine ingestion. These studies indicate that at the 
      levels reported, oral l-histidine supplementation is well tolerated and has 
      potential as a safe intervention for long-term use in the management of AD in all 
      age groups.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the 
      American Society for Nutrition.
FAU - Gibbs, Neil K
AU  - Gibbs NK
AD  - Dermatological Sciences, University of Manchester, Manchester, UK; and Curapel, 
      Stuart House, Chepstow, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Nutr
JT  - The Journal of nutrition
JID - 0404243
RN  - 0 (FLG protein, human)
RN  - 0 (Filaggrin Proteins)
RN  - 4QD397987E (Histidine)
SB  - IM
MH  - Adult
MH  - Child, Preschool
MH  - Dermatitis, Atopic/*drug therapy
MH  - *Dietary Supplements
MH  - Eczema/*drug therapy
MH  - Female
MH  - Filaggrin Proteins
MH  - Histidine/metabolism/pharmacology/*therapeutic use
MH  - Humans
MH  - Male
MH  - Skin/*drug effects/metabolism
OTO - NOTNLM
OT  - l-histidine
OT  - atopic dermatitis
OT  - eczema
OT  - filaggrin
OT  - skin barrier
EDAT- 2020/10/02 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/10/01 05:39
PHST- 2019/12/13 00:00 [received]
PHST- 2020/03/31 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/10/01 05:39 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - S0022-3166(22)02430-0 [pii]
AID - 10.1093/jn/nxaa200 [doi]
PST - ppublish
SO  - J Nutr. 2020 Oct 1;150(Suppl 1):2576S-2579S. doi: 10.1093/jn/nxaa200.